This Viewpoint discusses the basis for the FDA’s 2016 approval of the blood-based septin 9 gene (SEPT9) assay as a screening test for colon cancer and concerns about its accuracy and use in clinical practice.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados